There are 2867 resources available
722P - Modeling of tumor control probability (TCP) and normal tissue complications in individualized hypofractionated radiotherapy (IHRT) for large, advanced hepatocellular carcinoma (HCC)
Presenter: Sean Man Wong
Session: Poster session 13
723P - Medical expenditures and treatment efficacy of patients who had initial hepatocellular carcinoma and underwent surgery or radiofrequency ablation: Accompanying research of the SURF trial
Presenter: Yoshikuni Kawaguchi
Session: Poster session 13
725P - Identification of cuproptosis-related subtypes, the development of a prognosis model and drug candidates in HCC
Presenter: Yixiu Wang
Session: Poster session 13
726P - Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
Presenter: Mengya Zang
Session: Poster session 13
727TiP - A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3
Presenter: Ghassan Abou-Alfa
Session: Poster session 13
738P - Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial
Presenter: Maria Pouyiourou
Session: Poster session 13
740P - Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results
Presenter: Martin Gutierrez
Session: Poster session 13
741P - Phase I results demonstrate highly differentiated safety and PK profile of ADG126, a masked anti-CTLA-4 SAFEbody in patients with advanced solid tumors
Presenter: Gary Richardson
Session: Poster session 13